T.Y. has received research support for an N = 1 trial in ataxia telangiectasia from EveryONE Medicines, and is named as an inventor on three patents pertaining to antisense oligonucleotide treatments: for transposon-associated diseases (WO2019055460A1), ataxia telangiectasia (US20230174979A1), and progranulin (US11359199B2). Here, GRN is linked to ataxia telangiectasia.